4D Molecular Therapeutics (NASDAQ:FDMT) Stock Rating Lowered by BMO Capital Markets

BMO Capital Markets cut shares of 4D Molecular Therapeutics (NASDAQ:FDMT - Free Report) from an outperform rating to a market perform rating in a report issued on Monday, MarketBeat reports. BMO Capital Markets currently has $15.00 target price on the stock, down from their prior target price of $40.00.

Several other analysts have also commented on the stock. Leerink Partners reissued an "outperform" rating and set a $36.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research note on Thursday, September 19th. Morgan Stanley started coverage on 4D Molecular Therapeutics in a research note on Thursday, November 21st. They set an "underweight" rating and a $8.00 price objective for the company. HC Wainwright reaffirmed a "buy" rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a report on Monday. Bank of America dropped their price target on 4D Molecular Therapeutics from $79.00 to $46.00 and set a "buy" rating on the stock in a research note on Wednesday, December 18th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $39.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $38.56.

4D Molecular Therapeutics Price Performance

Shares of 4D Molecular Therapeutics stock traded down $0.76 during trading on Monday, hitting $4.76. The stock had a trading volume of 1,369,122 shares, compared to its average volume of 828,889. The business has a fifty day moving average of $6.94 and a two-hundred day moving average of $11.88. The firm has a market cap of $220.05 million, a P/E ratio of -1.67 and a beta of 2.81. 4D Molecular Therapeutics has a fifty-two week low of $4.68 and a fifty-two week high of $36.25.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Institutional investors have recently modified their holdings of the stock. Barclays PLC raised its position in 4D Molecular Therapeutics by 141.0% during the third quarter. Barclays PLC now owns 114,848 shares of the company's stock valued at $1,241,000 after acquiring an additional 67,202 shares in the last quarter. Y Intercept Hong Kong Ltd raised its holdings in shares of 4D Molecular Therapeutics by 81.3% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,538 shares of the company's stock valued at $265,000 after purchasing an additional 11,002 shares in the last quarter. State Street Corp lifted its stake in shares of 4D Molecular Therapeutics by 1.8% in the 3rd quarter. State Street Corp now owns 2,116,508 shares of the company's stock valued at $22,879,000 after purchasing an additional 37,232 shares during the last quarter. Redmile Group LLC boosted its holdings in 4D Molecular Therapeutics by 17.6% in the third quarter. Redmile Group LLC now owns 1,262,090 shares of the company's stock worth $13,643,000 after purchasing an additional 188,655 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of 4D Molecular Therapeutics during the 3rd quarter valued at about $166,000. Institutional investors and hedge funds own 99.27% of the company's stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.